CN101732688B - Amlodipine-containing medicament - Google Patents
Amlodipine-containing medicament Download PDFInfo
- Publication number
- CN101732688B CN101732688B CN2009102444171A CN200910244417A CN101732688B CN 101732688 B CN101732688 B CN 101732688B CN 2009102444171 A CN2009102444171 A CN 2009102444171A CN 200910244417 A CN200910244417 A CN 200910244417A CN 101732688 B CN101732688 B CN 101732688B
- Authority
- CN
- China
- Prior art keywords
- amlodipine
- chinese medicine
- ethanol
- medicine extract
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a synergistic medicinal composition containing amlodipine and Chinese medicinal extract, as well as the application of the composition in the preparation of medicaments for treating hypertension.
Description
Technical field
The invention belongs to a kind of medicine, a kind ofly specifically be used for the treatment of the hypertensive compositions that contains amlodipine.
Background technology
Hypertension is common clinical, frequently-occurring disease.A large amount of research is verified, and hypertension is the most important risk factor of cardiovascular and cerebrovascular disease.The whole nation is three hypertension census results show, nineteen fifty-nine the hypertension prevalence of being grown up more than 15 years old be 7.73% for 5.11%:1979; Rose to 11.8% in 1991, and be ascendant trend year by year.At present, there are hyperpietic 9,000 ten thousand people in the whole nation, increase 3,000,000 hypertensive patients every year newly, corresponding therewith, annual apoplexy new cases 1,500,000, about 1,000,000 people of person that die from the apoplexy every year, the existing about 500-600 ten thousand of apoplexy number of patients, wherein about 75% has lost work capacity to some extent, and severe disabled person accounts for more than 40%, annual economic loss and the medical expense that causes thus is quite surprising, brought serious social concern and heavy financial burden to country.So doing a good job of it with prevention, control hypertension is the cardiovascular and cerebrovascular disease preventing and controlling of breach, has been the task of top priority.
At present, though doctor trained in Western medicine has obtained certain progress to hypertensive research, new medicine comes out, and brings new hope to controlling blood pressure, and the most toxic side effect of hypotensor is often taken for a long time and brought many iatrogenic diseases to the patient, loses more than gain.The period in a medicine blood pressure drops, blood pressure easily bounces after the drug withdrawal, and effect is difficult to lasting.Though blood pressure descends sometimes, clinical symptoms is not removed, and what have increases the weight of on the contrary, and the labour force can not recover.And new depressor costs an arm and a leg mostly, and general patient is difficult to bear, and is not inconsistent inconvenient penetration and promotion with China's national situation.In the face of new problem, Chinese medicine has been cooked a large amount of work in recent years preventing and treating aspect the hypertension, obtained gratifying achievement, demonstrated certain advantage, but clinical practice is based on traditional decoction, though curative effect is preferably arranged, so time-consuming because of decocting, the waste medical material, the dosage form transmutability is big, be difficult to problems such as large tracts of land popularization, make the patient be difficult to adhere to for a long time, thereby influenced the normal performance of curative effect, do not reach the intended purposes of control.Filtered out a collection of single medicinal material, though take easy, but because of kind, limited amount, simultaneously, also simple because of the single practical application, can not embody the tcm characteristic that dialectical opinion is controlled, exist the limitation identical too with Western medicine, though be that blood pressure had decline after many patients took medicine, clinical symptoms does not subtract, the irreclaimable problem of labour force.
No matter the Chinese medicine hypertension is controlled in dialectical opinion, and single medicinal material is used and the zoopery aspect proves that all hypotensive effect is definite, and has and have no side effect, and curative effect is lasting, is difficult for advantages such as recurrence.But, be difficult to grasp unfavorable promoting the use because dialectical pattern of syndrome is unfixing.Some single medicine of hiding is effective in cure, but is difficult to solve simultaneous phenomenon, and the single drug effect a little less than, escalated dose problem such as easily have side effects again.
The present invention attempts Chinese medicine and Western medicine are combined, and with the problem of avoiding existing separately, and improves hypertensive therapeutic effect, promptly produces synergism.
Summary of the invention
One object of the present invention is to provide the Pharmaceutical composition of being made up of amlodipine and a kind of Chinese medicine extract, wherein prepares on the basis of the Chinese medicine extract of said composition according to the 6th page of specific embodiment of Chinese patent CN1150930C description, and is as follows:
Take by weighing 1 part of Ramulus Cinnamomi, 1 part of Radix Paeoniae Rubra, 1 part in Fructus Jujubae, 1 part in Rhizoma Zingiberis Recens, 0.7 part of Radix Glycyrrhizae Preparata, add 9 times distilled water, after water logging half an hour, heating extraction 2 times is boiled 30 minutes after-filtration at every turn, and residue discards, filtrate was reclaimed, and adds 70% ethanol precipitation, through 20 hours precipitations, decompress filter, discard residue, get and be dissolved in the ethanol part, reclaim ethanol, with 4 times of n-butanol extractions 7 times, each 2.5 hours n-butyl alcohol extractum.
One object of the present invention is to provide the purposes of above-mentioned Pharmaceutical composition in the hypertensive medicine of preparation treatment.
This Chinese medical concrete is called " the described Chinese medicine extract of this paper (or above) " hereinafter.
Above-mentioned composition and mixing acceptable accessories can be made acceptable forms clinically, as tablet, capsule, granule, oral liquid, subcutaneous administration preparation, suppository etc.
Pharmacological research
The main pharmacodynamics of Pharmaceutical composition of the present invention studies confirm that it has strong antihypertensive function, i.e. hypotensive activity.
The following medicine of respectively organizing is awarded spontaneous hypertensive rat (SHR) and mouthful raised administration 15 days, and the result all can obviously reduce the blood pressure of SHR.Experimental result sees the following form.
The test grouping:
1 model control group: after the animal model modeling success, normal physiological saline is irritated stomach;
2 pure Chinese drug-treated group: extractum 1.01g/kg body weight as indicated above
3 amlodipine groups: the 10mg/kg body weight is irritated stomach
4 compositions groups: 10mg/kg body weight amlodipine+extractum 1.01g/kg body weight mentioned above is irritated stomach.
This table shows that all there is significant difference (P＜0.05) in each group (pure Chinese drug-treated group, amlodipine group, compositions group) of treatment with model control group, and all there are significant difference (P＜0.05) in compositions group and pure Chinese drug-treated group, compositions group and amlodipine group.Show that there are cooperative effect in amlodipine and described Chinese medicinal components in the compositions group.
The pharmaceutics test
Can produce the tablet that contains following component in a conventional manner:
Component
The Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Corn starch 125.0
Pulvis Talci 75.0
Magnesium stearate 1.0
Wherein compositions is made up of with weight ratio amlodipine and described Chinese medicine extract at 1: 101.
Can produce the capsule that contains following component in a conventional manner:
Component
The Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Lactose 10.0
Corn starch 20.0
Pulvis Talci 5.0
Wherein compositions is made up of with weight ratio amlodipine and described Chinese medicine extract at 1: 101.
Claims (1)
1. treat hypertensive preparation of compositions method for one kind, it was made up of amlodipine and Chinese medicine extract in 1: 101 by weight, wherein Chinese medicine extract is obtained by following method: take by weighing by weight 1 part of Ramulus Cinnamomi, 1 part of Radix Paeoniae Rubra, 1 part in Fructus Jujubae, 1 part in Rhizoma Zingiberis Recens, 0.7 part of Radix Glycyrrhizae Preparata, the distilled water that adds 9 times, after water logging half an hour, heating extraction 2 times is boiled 30 minutes after-filtration at every turn, residue discards, filtrate was reclaimed, and adds 70% ethanol precipitation, through 20 hours precipitations, decompress filter, discard residue, get and be dissolved in the ethanol part, reclaim ethanol, with 4 times of n-butanol extractions 7 times, each 2.5 hours n-butyl alcohol extractum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102444171A CN101732688B (en) | 2009-12-30 | 2009-12-30 | Amlodipine-containing medicament |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102444171A CN101732688B (en) | 2009-12-30 | 2009-12-30 | Amlodipine-containing medicament |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101732688A CN101732688A (en) | 2010-06-16 |
| CN101732688B true CN101732688B (en) | 2011-09-14 |
Family
ID=42457056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102444171A Expired - Fee Related CN101732688B (en) | 2009-12-30 | 2009-12-30 | Amlodipine-containing medicament |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101732688B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102716370B (en) * | 2012-07-04 | 2014-07-02 | 施慧达药业集团(吉林)有限公司 | Pharmaceutical composition and application thereof |
| CN105796679A (en) * | 2016-03-27 | 2016-07-27 | 济南邦文医药科技有限公司 | Amlodipine-containing medicine composition for treating hypertension and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1150930C (en) * | 2001-10-26 | 2004-05-26 | 中国中医研究院中药研究所 | Cinnamon twig decoction extract for preventing and curing hypertension |
-
2009
- 2009-12-30 CN CN2009102444171A patent/CN101732688B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1150930C (en) * | 2001-10-26 | 2004-05-26 | 中国中医研究院中药研究所 | Cinnamon twig decoction extract for preventing and curing hypertension |
Non-Patent Citations (1)
| Title |
|---|
| 吕圭源.抗高血压药.《药理学》.中国中医药出版社出版,2003,189-190页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101732688A (en) | 2010-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101214304A (en) | Chinese medicine prescription for treating chronic cholecystitis | |
| CN100381163C (en) | Medicine comprising rilmenidine | |
| CN101007157A (en) | Traditional Chinese medicine compound preparation for treating chronic cholecystitis | |
| CN101732688B (en) | Amlodipine-containing medicament | |
| CN101773657B (en) | Medicine containing sodium nitroprusside | |
| CN105902762A (en) | Pharmaceutical composition for treating primary hypertension and preparation method and application thereof | |
| CN101732689B (en) | Minoxidil-containing medicament | |
| CN101708326B (en) | Medicine containing nifedipine | |
| CN101708325B (en) | Medicine containing propranolol | |
| CN100367956C (en) | Medicine for treating hypertension | |
| CN100367959C (en) | Medicine contg. irbesartan | |
| CN102068585B (en) | Chinese medicinal compound preparation for treating chronic nephritis and nephrotic syndromes | |
| CN105250954B (en) | A kind of Chinese medicine for treating IBS and preparation method thereof | |
| CN101732687B (en) | Methyldopa-containing medicament | |
| CN101810839B (en) | Diltiazem-containing medicine | |
| CN101732686B (en) | Metoprolol-containing medicament | |
| CN101439178B (en) | Medicament containing Urapidil | |
| CN101810840B (en) | Medicament containing terazosin | |
| CN101773658B (en) | Medicine containing indapamide | |
| CN101502635B (en) | Medicament composition containing Reserpine | |
| CN100425252C (en) | Medicine for treating leukopenia | |
| CN102552711B (en) | Traditional Chinese medicine composition for treating hypertension | |
| CN101773545B (en) | Leucocyte increasing medicament containing batyl alcohol | |
| CN1682855A (en) | Pressure lifting oral administration liquor of astragalus root | |
| CN102430073A (en) | Medicinal composition for treating peptic ulcer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: NINGBO YINZHOU AOSHENG BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: ZHANG XIXIN Effective date: 20110721 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Xiao Yu Inventor after: Zhang Xixin Inventor before: Zhang Xixin |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100020 B320, BUILDING 3, DACHENG INTERNATIONAL, NO. 80, EAST 4TH RING ROAD MIDDLE, CHAOYANG DISTRICT, BEIJING TO: 315194 ROOM 1308, TOWER A, NO. 1, HUAMAO XUEFU, SHOUNAN SUBDISTRICT, YINZHOU DISTRICT, NINGBO CITY, ZHEJIANG PROVINCE Free format text: CORRECT: INVENTOR; FROM: ZHANG XIXIN TO: XIAO YU ZHANG XIXIN |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20110721 Address after: 315194 Zhejiang city of Ningbo province Yinzhou District South Street Huamao a number of institutions A building room 1308 Applicant after: Ningbo Yinzhou Aosheng Biological Technology Co., Ltd. Address before: 100020, B320, building 3, Dacheng International, No. 80 East Fourth Ring Road, Beijing, Chaoyang District Applicant before: Zhang Xixin |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110914 Termination date: 20111230 |